amodiaquine has been researched along with Neglected Diseases in 2 studies
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.
amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.
Neglected Diseases: Diseases that are underfunded and have low name recognition but are major burdens in less developed countries. The World Health Organization has designated six tropical infectious diseases as being neglected in industrialized countries that are endemic in many developing countries (HELMINTHIASIS; LEPROSY; LYMPHATIC FILARIASIS; ONCHOCERCIASIS; SCHISTOSOMIASIS; and TRACHOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| " One example of such initiatives is the Fixed-Dose Artesunate Combination Therapy (FACT) project consortium, which brought together institutions with different natures from both the North and the South, for the development of two antimalarial fixed-dose combinations recommended by the WHO - artesunate-amodiaquine (ASAQ) and artesunate-mefloquine (ASMQ)." | 3.80 | Needs-driven versus market-driven pharmaceutical innovation: the consortium for the development of a new medicine against malaria in Brazil. ( Kameda, K, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kameda, K | 1 |
| Maxmen, A | 1 |
2 other studies available for amodiaquine and Neglected Diseases
| Article | Year |
|---|---|
Needs-driven versus market-driven pharmaceutical innovation: the consortium for the development of a new medicine against malaria in Brazil.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Brazil; Drug Combinations; Drug Discovery; Dru | 2014 |
Busting the billion-dollar myth: how to slash the cost of drug development.
Topics: Africa; Amodiaquine; Anti-Bacterial Agents; Artemisinins; Benzamides; Boron Compounds; Child; Clinic | 2016 |